Genzyme
Also known as: BioMarin/Genzyme LLC | Corp. GCP Compliance - Clinical Affairs, Genzyme Japan K.K. | Diacrin/Genzyme Corporation LLC | GENZYME | Genzyme, a Sanofi Company | Genzyme Coorporation | GENZYME CORP | Genzyme Corporation | Genzyme Europe B.V. | Genzyme Europe, B.V.
Highest phase reached
Phase 4
First clinical trial
Jul 1, 1997First marketed drug
Apr 5, 1991First NDA
Apr 5, 1991Last known activity
Jul 31, 2025
Timeline
1980s
- Jan 1, 1981
Genzyme— Founded
1990s
- Apr 5, 1991
alglucerase— NDA Organization
- Jan 1, 1997
PharmaGenics— Acquired
- Oct 30, 1998
sevelamer— NDA Secondary Org
- Jan 1, 1999
Cell Genesys— Acquired
- Jan 1, 1999
Peptimmune— Acquired
2000s
- Jan 1, 2000
Biomatrix, Inc— Acquired
- Jan 1, 2000
GelTex Pharmaceuticals— Acquired
- Jan 1, 2001
Focal, Inc— Acquired
- Jan 1, 2001
Novazyme Pharmaceuticals— Acquired
- Sep 10, 2003
Sangstat Medical Corporation— Acquired
- Jan 1, 2004
ILEX— Acquired
- Jan 1, 2005
Bone Care International— Acquired
- Jan 1, 2005
Verigen AG— Acquired
- Jan 1, 2006
AnorMED— Acquired
- Apr 28, 2006
alglucosidase alfa— Marketing Organization
- Oct 1, 2007
Bioenvision— Acquired
2010s
- Jan 1, 2011
Sanofi-Aventis— Acquired By
Drugs by trial phase (187 distinct, 460 trials)
Phase 4 (31 own, 4 via acquisition)
Phase 3 (38 own, 5 via acquisition)
Phase 2 (64 own, 11 via acquisition)
Phase 1 (26 own, 2 via acquisition)
Other trials (6 own, 0 via acquisition)
Indications
Approved for
Studied for
- Acquired Immunodeficiency Syndrome
- Acute Disease
- Adenocarcinoma
- Amino Acid Metabolism, Inborn Errors
- Anemia
- Anemia, Aplastic
- Aphasia, Primary Progressive
- Astrocytoma
- Atherosclerosis
- beta-Thalassemia
- Biliary Tract Neoplasms
- Blast Crisis
- Brain Neoplasms
- Breast Neoplasms
- Burkitt Lymphoma
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Medullary
- Carcinoma, Neuroendocrine
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Renal Cell
- Cardiomyopathies
- Cardiovascular Diseases
- Cartilage Diseases
- Cholangiocarcinoma
- Clostridium Infections
- Colitis
- Colorectal Neoplasms
- Congenital Abnormalities
- Coronary Artery Disease
- Coronary Disease
- Crohn Disease
- Deficiency Diseases
- Delayed Graft Function
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Diabetic Foot
- Diabetic Nephropathies
- Diarrhea
- Disease
- Dyslipidemias
- Endometrial Neoplasms
- Enterocolitis
- Enterocolitis, Pseudomembranous
- Eye Diseases
- Fabry Disease
- Fallopian Tube Neoplasms
- Fibrosis
- Foot Ulcer
- Fractures, Stress
- Frontotemporal Dementia
- Gallbladder Neoplasms
- Gaucher Disease
- Genetic Diseases, Inborn
- Glioblastoma
- Glioma
- Gliosarcoma
- Glomerulosclerosis, Focal Segmental
- Glycogen Storage Disease
- Glycogen Storage Disease Type II
- Goiter
- Graft vs Host Disease
- Heart Diseases
- Heart Failure
- Hemophilia A
- Hemophilia B
- HIV Infections
- Hodgkin Disease
- Hypercholesterolemia
- Hyperlipidemias
- Hyperlipoproteinemias
- Hyperlipoproteinemia Type II
- Hyperparathyroidism
- Hyperparathyroidism, Secondary
- Hyperphosphatemia
- Hypobetalipoproteinemias
- Hypolipoproteinemias
- Hypoxia
- Idiopathic Pulmonary Fibrosis
- Immunoblastic Lymphadenopathy
- Infant, Newborn, Diseases
- Intermittent Claudication
- Iron Overload
- Ischemia
- Kidney Diseases
- Kidney Failure, Chronic
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Leukemia, Myelomonocytic, Acute
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Myelomonocytic, Juvenile
- Leukemia, Prolymphocytic
- Leukemia, Prolymphocytic, T-Cell
- Leukemia, Promyelocytic, Acute
- Lipid Metabolism Disorders
Marketed drugs (19)
Subsidiaries (13 direct, 14 total across the full acquisition tree)
Recent trials (50)
- NCT07087106CollaboratorPhase 4Jul 31, 2025
- NCT06666413Lead sponsorPhase 4Mar 27, 2025
- NCT05911321CollaboratorPhase 2Dec 30, 2023
- NCT06121180CollaboratorPhase 2Oct 31, 2023
- NCT05401786CollaboratorPhase 2Jun 30, 2022
- NCT05247866CollaboratorPhase 4Jun 16, 2022
- NCT05280548Lead sponsorPhase 3May 3, 2022
- NCT05222906Lead sponsorPhase 3Apr 18, 2022
- NCT05164055Lead sponsorPhase 4Feb 15, 2022
- NCT05346809CollaboratorPhase 2Feb 9, 2022
- NCT04873375CollaboratorPhase 2Oct 31, 2021
- NCT05134571Lead sponsorPhase 4Oct 28, 2021
- NCT05054387Lead sponsorPhase 4Oct 13, 2021
- NCT04883242CollaboratorPhase 2Jul 29, 2021
- NCT04676373Lead sponsorPhase 4Jan 13, 2021
Details
- Founded
- Boston, MA, US Jan 1, 1981
- First NDA
- Apr 5, 1991
- Last known activity
- Jul 31, 2025
Designations held
- Orphan drug
- Fast track
- Priority review
- Accelerated approval